Cabaletta Bio reports $164M cash, expands rese-cel trials into MS, MG, PV; FDA meeting planned 1H25

Cabaletta Bio, Inc.

Unaudited cash $164M as of Dec 31, 2024; funds operations into H1 2026.
21 patients enrolled across 44 RESET sites in US/Europe; safety data: 90% no CRS/grade 1, 90% no ICANS.
First patients enrolled in RESET-PV (no preconditioning) and RESET-MG; RESET-MS IND cleared with Fast Track.
Expanded CDMO agreement with Lonza for clinical supply from H2 2025.
Plans to meet FDA in 1H 2025 to align on registrational trial designs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.